Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021


HomeCLINICAL TRIALS, STUDIES, DATAGynesonics Announces Publication of SAGE Global Registry Preliminary Results

Gynesonics Announces Publication of SAGE Global Registry Preliminary Results

April 16, 2021

Gynesonics today announced the publication of its peer-reviewed journal article, “Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results,” in the journal Medical Devices: Evidence and Research.

The article reported that of 241 fibroids treated by the Sonata® System, 10 percent were submucous, 52 percent transmural, 28 percent intramural, and 10 percent subserous.  Ablated fibroid diameters ranged from <1 cm to >10 cm, with 27 percent of fibroids having maximum diameters >5 cm.  Additionally, the preliminary results indicated the Sonata System maintained its established safety profile with very low device-related adverse event and serious procedure-related adverse event rates of 0.6 percent for both measures.  These initial results corroborate those from previous clinical trials, as well as more than 1,800 commercial cases worldwide.

“The SAGE registry represents the largest clinical study to date of transcervical fibroid ablation (TFA) and will generate up to 2,500 patient-years of outcomes data,” said Dr. Ladina Christoffel, Head of Gynecology and Obstetrics at the Spital Oberengadin-Schweiz in Samedan, Switzerland.

Christoffel added, “The real-world outcomes derived from SAGE will further strengthen the existing evidence on the durability of TFA and the Sonata System in providing meaningful relief from uterine fibroid symptoms as well as having important positive clinical and economic implications for patients, physicians and healthcare payers.  It is impressive to see the wide range of fibroid types treated, as most of these could not be treated by operative hysteroscopy, and TFA, as performed by the Sonata System, allows women to avoid the much more invasive options of myomectomy or hysterectomy.”

In the SAGE Registry, eligible patients are adult women (age ≥18 years) with symptomatic uterine fibroids who select TFA for treatment of their fibroids.  No limitations are imposed on maximum patient age, fibroid type, fibroid size, prior surgical history, baseline symptom severity, or desire for future fertility.  The registry will follow women for 5 years, after which a comprehensive characterization of long-term, real-world outcomes of TFA will be possible.

“We are incredibly pleased to see the SAGE Registry initial results indicate that in real world conditions, women with a very wide range of fibroid types, locations and sizes can be successfully treated with TFA utilizing the Sonata System,” said Taraneh G. Farazi, Ph.D. and Vice President, Clinical Affairs at Gynesonics.  “These safety results are completely aligned with data from multiple clinical studies utilizing Sonata.  For the millions of women who want to avoid more invasive procedures such as myomectomy or hysterectomy, there is now a safe and effective alternative treatment for their symptomatic fibroids, with excellent long-term results.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy